ATARA BIOTHERAPEUTICS INC (ATRA)
US0465131078 - Common Stock
Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
ATRA Stock Earnings: Atara Biotherapeutics Misses EPS, Misses Revenue for Q4 2023
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Atara Biotherapeutics (NASDAQ:ATRA) just reported results for the fourth quarte...
ATRA Stock Earnings: Atara Biotherapeutics Misses EPS, Misses Revenue for Q4 2023
ATRA stock results show that Atara Biotherapeutics missed analyst estimates for earnings per share and missed on revenue for the fourth quarter of 2023.
Atara Biotherapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Operational Progress
FDA clears Atara to begin Phase 1 study for lupus nephritis drug (NASDAQ:ATRA)
Atara Biotherapeutics (ATRA) said the FDA has cleared its application to begin Phase 1 testing of its immunotherapy ATA3219 for the treatment of lupus nephritis. Read more here.
Atara Biotherapeutics Receives FDA Clearance of IND Application in Lupus Nephritis for ATA3219, an Allogeneic CAR T Therapy
Atara Biotherapeutics to Participate in Cell Therapy Panel Discussion at the Cowen 44th Annual Health Care Conference
Atara Biotherapeutics Announces Submission of Investigational New Drug Application for ATA3219 for Treatment of Lupus Nephritis
Atara Biotherapeutics y Pierre Fabre Laboratories publica los datos de fase 3 ALLELE Tab-cel®
/PRNewswire/ -- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), líder en inmunoterapia con células T, aprovecha su nueva plataforma alogénica de células T del...
Atara Biotherapeutics und Pierre Fabre Laboratories geben Veröffentlichung von Phase-3-Daten zu ALLELE Tab-cel® in der Fachzeitschrift „The Lancet Oncology" bekannt
/PRNewswire/ -- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), ein führendes Unternehmen im Bereich der T-Zell-Immuntherapie, das mit seiner neuartigen allogenen...
Atara Biotherapeutics et les Laboratoires Pierre Fabre annoncent la publication des résultats de l'étude ALLELE de phase III portant sur le Tab-cel® dans The Lancet Oncology
/PRNewswire/ -- Atara Biotherapeutics Inc. (Nasdaq : ATRA), leader dans le domaine de l'immunothérapie à cellules T, qui tire parti de sa plate-forme novatrice...
Atara Biotherapeutics and Pierre Fabre Laboratories Announce Publication of Phase 3 ALLELE Tab-cel® Data in The Lancet Oncology
/PRNewswire/ -- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell...
Atara Biotherapeutics and Pierre Fabre Laboratories Announce Publication of Phase 3 ALLELE Tab-cel® Data in The Lancet Oncology
Commit To Buy Atara Biotherapeutics At $0.50, Earn 24.2% Annualized Using Options
Atara to conduct $15M registered direct offering (NASDAQ:ATRA)
Atara Biotherapeutics (ATRA) plans to conduct a $15M registered direct offering. Read more here.
Atara Biotherapeutics Announces $15 Million Registered Direct Offering
Atara Biotherapeutics to Present Recent Progress and Key Upcoming Milestones at the 42nd Annual J.P. Morgan Healthcare Conference
Atara Biotherapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Friday Sector Leaders: Trucking, Biotechnology Stocks
Atara Biotherapeutics Announces Closing of Expanded Global Tab-cel® Partnership with Pierre Fabre Laboratories
Atara reportedly laying off 73 workers in wake of failed MS drug study (NASDAQ:ATRA)
Atara Biotherapeutics (ATRA) is reportedly laying off 73 employees in California in the wake of a failed Phase 2 study for its multiple sclerosis drug candidate
Atara Biotherapeutics Presents Positive Preclinical Data on ATA3431, A Next-Generation Allogeneic CD20/CD19-Targeted CAR, at the 65th ASH Annual Meeting
Atara Biotherapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Atara Biotherapeutics To Present Positive New Tab-cel® Clinical Data During Oral Session at ESMO Immuno-Oncology Annual Congress 2023
